February 5, 2010 — Results from 8 clinical trials show that recombinant human thrombin (rThrombin; Recothrom, ZymoGenetics, Inc) is well tolerated in several surgical settings for topical hemostasis ...

Does re-exposure to recombinant human thrombin result in sensitization? The authors investigated this problem in 31 adult patients who had previously been exposed to recombinant human thrombin during ...

ZymoGenetics Inc. opened a broad Phase II program of recombinant human Thrombin (rhThrombin), which is being developed to control bleeding during surgery. The Seattle-based company began a Phase II ...

Co announces it has entered into multi-year, domestic and global license and collaboration agreements with Bayer HealthCare (BAY) to maximize the potential of ZymoGenetics' recombinant human thrombin ...

Thrombin-jmi Clinical Trials Clinical Trials In a double-blinded, controlled trial, patients were randomly assigned to receive Thrombin-JMI (n=206) or recombinant human thrombin (n=205) as adjuncts to ...

Seattle’s ZymoGenetics, now the largest biotech based in the region, announced today that the FDA has accepted its application for recombinant human thrombin, a bleeding-control drug candidate.

Transthyretin amyloid (ATTR) cardiomyopathy is a progressive and fatal disease caused by misfolded transthyretin. Despite advances in slowing disease progression, there is no available treatment that ...

LONDON (MarketWatch) -- ZymoGenetics Inc zgen said the U.S. Food and Drug Administration will not require additional clinical trials with recombinant human Thrombin administered by a spray device. The ...